The effect of iv glucagon injections on growth hormone (GH) 
tion. Among these, insulin-induced hypoglycaemia (Roth et al. 1963 ; Green¬ wood et al. 1966; Glick et al. 1965 ) and arginine infusion (Knopf et al. 1965; Merimee et al. 1965; Parker et al. 1967 ) have been most widely used.
However, the possible dangers of hypoglycaemia, and doubts as to the relia¬ bility of arginine which readily stimulates GH secretion in women, but not in every normal man (Merimee et al. 1966 ) , and which, moreover, in controlled experiments in adults, no more frequently induces increases in GH than saline infusions only (Best et al. 1968 ), have stimulated a search for other methods. Recently, Mitchell et al. (1969) described good reproducible elevations of plasma GH levels in adults of either sex within 2 hours following the subcutaneous administration of 1 mg of glucagon. Intramuscular injections of the hormone (0.03 mg/kg) induced a very similar effect in normal as well as in genetically tall and short children and adolescents (AvRuskin et al. 1968) .
In diabetic, but not in normal children, Drash et al. (1968) (Milner & Wright 1967) . No effect on GH values was noted in 2 adults (Roth et al. 1963b ).
Random observations of plasma GH increases in normal children shortly after intravenous glucagon loads (1 mg), encouraged us to investigate immunoreactive GH values in plasma samples of normal weight, obese, and diabetic children, in whom glucagon had been given for studies of insulin secretion se¬ veral hours after tolbutamide loads or arginine tests. For comparison, some sub¬ jects were investigated for this purpose only. They either received only gluca¬ gon, or saline infusions or injections followed by glucagon administration. The results indicate that in many normal children, and, less frequently, in obese sub¬ jects and diabetic patients, glucagon induces pituitary GH release.
MATERIAL AND METHODS
45 children and adolescents have been grouped into normal weight (n = 23), over¬ weight (120% of normal weight and over"', n= 12), and insulin-dependent diabetic patients (n = 10). Data on age, height, and weight of these children, as well as some information about the nature and duration of other tests preceding the intravenous injection of glucagon, are given in Table 1, while individual values of glucose and  GH measurements are shown in Tables 2 and 3 . The glucose-and GH responses to glucagon of a 14 year old boy who underwent bilateral adrenalectomy in 1964 and developped precocious puberty and radiological signs of an intrasellar tumour were not included in these tables and are presented elsewhere (see Fig. 3 ).
All children were In-Patients. The diabetics and most of the obese children were referred to hospital for treatment, while the normal weight and some of the less obese subjects were recovering from minor non-endocrine disorders. Six of the diabetics had been treated with regular insulin for several days. None of these patients received insulin on the morning before the investigation. In the remainder, treatment was with¬ held until after the glucagon test.
The investigations were done during bed rest, following a 14 hour overnight fast. After local anaesthesia, a plastic cannula was inserted into an antecubital vein, from which blood samples were drawn into heparinized tubes 15 min, immediately before, and 2, 5, 10, 20, 30, 40, 50 , and 60 min after the administration of glucagon. 1 mg of the hormone (Novo or Lilly) which showed no cross-reaction with GH antibodies, was injected into the same cannula,' irrespective of the children's weight or surface area. When glucagon was administered at the end of another investigation, the same cannula was used for both tests. By this procedure, the stress of another cannulation was avoided. In these cases, only one basal pre-injection level of GH and blood sugar, respectively, has been listed.
Most subjects showed short-lasting signs of discomfort and nausea, sometimes ab¬ dominal spasms between 2 and 5 min after glucagon injection; a few vomited (Table  5) . None of the tests had to be interrupted for this reason.
Blood sugar was measured by the ferricyanide method (Hoffman 1937) , adapted to the autonalyzer, and plasma GH by a double antibody radioimmunoassay (Quabbe 1969) , free and antibody-bound hormone being separated by immunoprecipitation. The sensitivity of this assay was such, that it was possible to differenciate between 0.5 to 1.0 ng/ml and 0.0. The reproducibility of plasma values was satisfactory. Repeated assays of a control plasma sample with a mean concentration of 2.9 ng/ml (n = 33) gave a sem of 0.12 ng/ml (Quabbe 1969) . (Table 2) Blood sugar levels increased following glucagon injection in almost all sub¬ jects, reaching maxima after 20 to 30 min, after which they decreased. Pretest values were similar in the normal weight and obese groups, the increase after glucagon administration being a little higher in the former. In the diabetics, all mean values ranged about 60 mg/100 ml above those of the other children.
The mean increments of blood sugar within 20 min after the injection of glucagon were 54, 43, and 54 mg/100 ml in the normal, obese, and diabetic groups, respectively, The secondary fall in blood sugar was slower in the dia¬ betics, the 60 min value remaining 32 mg/100 ml above the pretest level, as compared to 8 mg/100 ml in the normal weight and obese children.
2. Growth Hormone (Tables 3, 4, and 5) Plasma GH increases of variable magnitude were observed in 15 out of 23 normal children. In view of the high sensitivity of the assay used, increments of 2 ng/ml were arbitrarily regarded as representing the lower limit of »response«.
In many instances the rise in plasma GH levels began 2 to 5 min after the glucagon injection and reached maximal values 5 to 25 min later. This type of Heimendinger (1958) 
basal level of 1.8 ng/gl (-15 min) to a maximum of 7.8 ng/ml (2 min) which commenced before the injection and thereafter continued. This response was also not attributed to glucagon.
Changes in GH values in those normal subjects showing »high« levels (about 10 ng/ml and more, including the pretest levels of subjects 4 and 19, see Table  3 ) before glucagon injection were not regarded as representing responses to the hormone, even if they exceeded the limit mentioned above. The secondary in- of GH of more than 2 ng/ml, and only 2 of these increments exceeded 4 ng/ml.
Only 3 out of 10 children with recently discovered diabetes mellitus showed increases in GH after glucagon administration which in all 3 were very dis¬ crete and just surpassed the arbitrary limit. In 3 of the remaining »non-respon- Some experiments are presented separately in Fig. 2 . In 5 normal children a saline solution (0.9 g/100 ml) was infused or injected (slow rate infusion or 10 ml at once), followed 3 h later by intravenous injections of glucagon, using the same cannula. Of these subjects, one (J. A.) had a high fasting value of GH (not identical with the pre-glucagon level registered in In some subjects (12, 13, and 17, as well as in M. N. and J. D. (Fig. 2) ) the insertion of a cannula into a forearm vein by ifself may have been responsible for the increase in GH values between F (-15 min) and 0 min, since children, contrary to adults, do show rather frequent increases in GH values following venous cannulation under the conditions described above (Helge et al. 1969 ). These changes are probably due to the non-specific stress of this procedure. Therefore, the practice of observing a 15 min control period before the admini¬ stration of the test agent seems to be useful, and makes it possible to diffe¬ rentiate between those responses due to cannulation and those attributable to the agent investigated.
When the effectiveness of cannulation and glucagon injection with regard to GH release is compared, the hormone seems to elicit increases in GH more regularly (see Fig. 2 ). (Fig. 2) showing a higher incidence of GH increases following glucagon as compared to the non-specific stress of venous cannulation are in agreement with this view.
The concept of a stress-like action of glucagon on GH release offers no ex¬ planation for the low incidence of GH rises in the diabetic children. The higher blood sugar levels of these patients should be unimportant in this respect, since the overall responsiveness of diabetics to different stimuli of GH secretion is not impaired (Parker et al. 1968; Baker et al. 1969; Hunter et al. 1966; Glick et al. 1965 (Schofield 1967 (Roth et al. 1963 & ; Schalch 1967) . If, however, catecholamine secretion were impaired after total adrenalectomy, the rapid increase in GH values in our patient (Fig. 3) (Müller et al. 1967a (Müller et al. ,b, 1968 indicate some adrenergic control of GH secretion at the hypo¬ thalamic level.
Significant alterations in GH responses to insulin-induced hypoglycaemia in man, following the use of a-and ß-adrenergic blocking agents (Blackard 8c Heidingsfelder 1968) seem to confirm these studies. Whether or not glucagon is capable of exerting some effect on hypothalamic adrenergic receptors which may mediate in GHRF-and GH-production, is at present unknown.
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